VericelVCEL
Recorded

Vericel 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration56 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day and welcome to the Vericel Corporation Third Quarter 2026 Earnings Call. Today's conference is being recorded. If you would like to ask a question on today's call, please press star one on your telephone keypad. Now, at this time, I would like to turn the conference over to Eric Burns, Vericel VP of Finance and Investor Relations.

Eric BurnsVP of Finance and Investor Relations

Please go ahead, sir. Thank you, operator, and good morning, everyone.

Eric BurnsVP of Finance and Investor Relations

Joining me on today's call are Vericel's President and Chief Executive Officer, Nick Colangelo, and our Chief Financial Officer, Joe Mara. Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially from expectations are discussed more fully in the company's most recent filings with the SEC. Also, the discussions today will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release, which is included as an exhibit to Vericel's current report on Form 8-K filed today with the SEC. A short presentation with highlights from today's call is also available in the Investor Relations section of our website. I will now turn the call over to Nick.

Nick ColangeloPresident and CEO

Thank you, Eric, and good morning, everyone. The company had an outstanding third quarter, which was the strongest quarter of the year on a number of measures for the company, MACI, and our burn care business, as we generated top-tier revenue growth across the portfolio, an inflection in profitability, and significant free cash flow. We delivered record third quarter total revenue of more than $85 million, which increased 26% over last year and significantly exceeded our guidance for the quarter. Based on our third quarter outperformance and the strong momentum that has continued into the fourth quarter, we are raising our full year total revenue guidance to $344 million-$346 million, which represents 25% revenue growth for the year at the midpoint and an increase in revenue guidance of nearly $25 million since the start of the year.

Nick ColangeloPresident and CEO

We also had another excellent quarter from a profitability perspective, as net income nearly tripled, adjusted EBITDA grew nearly 50% to more than $25 million, and adjusted EBITDA margin increased to 30%, which was significantly higher than our guidance for the quarter. Based on this outperformance on profitability measures, we are also raising our adjusted EBITDA margin guidance for the year. MACI had another great quarter with record third quarter revenue of more than $67 million, which exceeded our guidance for the quarter and increased 21% versus the prior year, marking the sixth consecutive quarter with MACI revenue growth of 20% or more, which was notable given the significant acceleration in MACI implant and revenue growth in the third quarter of last year. Beyond MACI's strong revenue performance, we continue to see significant momentum in the underlying business fundamentals that support sustained MACI growth.

Nick ColangeloPresident and CEO

We achieved record third quarter MACI biopsies, implants, and biopsy and implanting surgeons. Importantly, MACI's biopsy growth rate has increased each quarter this year, and we started the fourth quarter with the strongest biopsy month since launch in October, reflecting the strong demand that is translating into the robust implant procedure volume that supports our increased fourth quarter revenue guidance. With continued momentum across our key growth indicators and a strong start to the fourth quarter, we believe that MACI is exceptionally well-positioned to deliver a strong finish to the year and sustain its growth trajectory in 2027 and beyond. MACI's strong performance has been driven by the consistent high level of execution of our expanded MACI sales force, as well as the impact of the MACI Arthro launch and our commercial excellence initiatives.

Nick ColangeloPresident and CEO

The primary objective of our sales force expansion and commercial initiatives is to drive deeper penetration within MACI surgeon practices, and during the third quarter, we saw continued strength in biopsies per surgeon, a clear indicator that this initiative is beginning to unlock another key growth driver for MACI. In addition, the cohort of expansion territories has the highest biopsy growth rate for the first three quarters of the year, which we expect will lead to accelerating implant growth in our new territories in the fourth quarter and into 2027. MACI Arthro adoption also continues to gain momentum. We completed a record number of MACI Arthro procedures in the third quarter, which represented the highest percentage of total MACI procedures in any quarter since launch.

Nick ColangeloPresident and CEO

We also had a record high number of surgeons perform a MACI Arthro procedure in the quarter, and more than 25% of MACI procedures to treat condyle defects under four square centimeters were administered via MACI Arthro, another strong indicator of increasing adoption. While the patella defect segment continues to be our highest volume and growth segment, we have also seen higher growth and activity in other defect locations, which we believe is a result of the focus MACI Arthro has created for these other defect segments. We expect that expanding MACI Arthro adoption and utilization will be further supported by a growing body of positive clinical evidence. Of note, a recent publication evaluating patients treated arthroscopically outside the United States reported durable clinical outcomes and a higher rate of patient satisfaction at a mean follow-up of 13.6 years, reinforcing the potential long-term clinical benefits with the arthroscopic delivery of MACI.

Nick ColangeloPresident and CEO

In addition, the first MACI Arthro publication, which was published in August, highlighted several surgical and early patient outcome advantages of the MACI Arthro procedure, including minimal surgical disruption to the joint, the ability to treat multiple cartilage defects in different compartments of the knee, a more desirable cosmetic appearance, and improved early postoperative recovery. These initial results suggest positive patient outcomes that could also lead to shorter overall rehab and recovery timelines for MACI Arthro patients. Looking ahead, we expect our MACI clinical outcomes registry to expand to even more sites in 2027, leading to additional data for future publications that can further enhance MACI's strong clinical profile. Surgeon engagement with MACI also continues to significantly expand as the number of peer-to-peer programs and training labs through the third quarter have more than tripled compared to last year.

Nick ColangeloPresident and CEO

As we move into 2027, we expect an even greater impact from the expanded MACI sales force, MACI Arthro adoption, and our commercial excellence initiatives, which together with continued overall trends towards restorative cartilage repair procedures, positions MACI for sustained strong growth in 2027 and beyond. In terms of our longer-term MACI growth drivers, we continue to activate sites and enroll patients in the MACI Ankle MASCOT study. As a reminder, a potential MACI Ankle indication represents a substantial commercial opportunity for the company, with an estimated annual addressable market of nearly 20,000 patients, representing more than a $1 billion market opportunity. We also remain on track for the potential launch of MACI in the U.K. in the second half of 2027, which represents another meaningful market opportunity.

Nick ColangeloPresident and CEO

Based on procedural data available from the U.K. National Health Service, we estimate an addressable market of approximately 15,000 patients annually, representing a potential market opportunity of several hundred million dollars. As we noted on our last call, we submitted a MACI marketing authorization application to the U.K. in the second quarter. The MHRA completed its inspection of our new manufacturing facility in the third quarter, and earlier this month, NICE accepted MACI for a single technology appraisal, which will establish reimbursement and pricing, as well as a specific MACI funding guidance for the NHS. In parallel, we have begun initial market development work to assess additional MACI OUS expansion opportunities in Canada and Europe.

Nick ColangeloPresident and CEO

Finally, we are continuing to develop the next generation of MACI Arthro instruments, as we remain focused on continuous innovation to further simplify and reduce surgical time for the MACI Arthro procedure, and providing greater access for all areas of the knee, including for patella defects, which we expect will support sustained increases in surgeon engagement and MACI utilization. The company also delivered an exceptional quarter for the burn care business, as we built on the momentum from the first half of the year and generated the highest quarterly revenue to date for both Epicel and NexoBrid, with record quarterly burn care revenue of $18 million, representing more than 50% growth versus both the prior year and the prior quarter. Epicel's record quarterly revenue is driven by continued strength in biopsies and new biopsying centers, as the burn care commercial team's cross-selling efforts continue to expand Epicel adoption and utilization.

Nick ColangeloPresident and CEO

NexoBrid's record quarterly commercial revenue was driven by the highest number of ordering burn centers and hospital orders in any quarter to date. Notably, we have added more new NexoBrid ordering centers through the third quarter this year than during all of last year, and have continued to expand the number of consistent users, an important driver of further uptake. To date, more than 80 centers have placed NexoBrid orders, with approximately 70 centers having placed repeat orders, as we continue to focus on driving more centers to become consistent users. Building on the success with MACI, we have also recently implemented several commercial and operational excellence initiatives across burn care that we believe are beginning to have a meaningful impact on performance.

Nick ColangeloPresident and CEO

For Epicel, we began the year with a full commercial rebranding that refreshed the product's positioning around the critical importance of achieving wound closure, significantly increased our peer-to-peer activity, and sharpened our focus on supporting our surgeon customers with a multidisciplinary approach to drive the best clinical outcomes for patients. For NexoBrid, we have implemented similar account planning as well as stakeholder mapping initiatives that are leading to broader standardization of treatment algorithms across burn centers and more consistent adoption and utilization of NexoBrid. As we move into 2027, we believe that these commercial initiatives and our enhanced execution can drive continued strong results for the burn care franchise. Overall, we are on track to deliver a strong close to the year and another great year for the company. Our recent financial results and increased guidance demonstrate the company's unique combination of sustained high revenue growth, profitability, and cash generation.

Nick ColangeloPresident and CEO

We believe that the durable growth of our portfolio positions the company to sustain strong revenue and profit growth in 2027 and the years ahead, as we remain on track to achieve our midterm revenue and profitability targets. I will now turn the call over to Joe to discuss our third quarter results and updated 2026 guidance in more detail.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day